Xuedong Liu /biochemistry/ en ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Biochemistry Professor Xuedong Liu Recognized as an elite member of the 2024 Class of Fellows by the National Academy of Investors (NAI) /biochemistry/2024/12/16/cu-boulder-biochemistry-professor-xuedong-liu-recognized-elite-member-2024-class-fellows ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Biochemistry Professor Xuedong Liu Recognized as an elite member of the 2024 Class of Fellows by the National Academy of Investors (NAI) Jessica Helzer Mon, 12/16/2024 - 11:03 2024 Faculty Awards Faculty Highlights Xuedong Liu

ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Biochemistry Professor, Xuedong Liu, was announced as a member of the 2024 Class of Fellows by the on December 10th, among an elite elected group of 170 exceptional inventors. is the highest professional distinction awarded solely to inventors. The full list of 2024 Fellows can be found .

The 2024 cohort of Fellows exemplifies the Academy’s belief that groundbreaking innovation knows no bounds and inventors can be found everywhere. This is evident in the fact that the honorees represent 39 U.S. states, 12 countries, and 43% identify as underrepresented inventors. 

The 2024 Class of Fellows will be honored and presented their medals by a senior official of the United States Patent and Trademark Office (USPTO) at the on June 26th, 2025 in Atlanta, Georgia.

ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Biochemistry Professor, Xuedong Liu, was announced as part of the 2024 Class of Fellows by the National Academy of Inventors (NAI) on December 10th, where NAI announced the election of 170 exceptional inventors into the 2024 Class of Fellows. NAI Fellowship is the highest professional distinction awarded solely to inventors.

Off

Traditional 0 On White ]]> Mon, 16 Dec 2024 18:03:46 +0000 Jessica Helzer 1541 at /biochemistry Biochemistry Professor Xuedong Liu's startup, OnKure Therapeutics, raises $51M in series B funding in 2021 /biochemistry/2022/03/03/biochemistry-professor-xuedong-lius-startup-onkure-therapeutics-raises-51m-series-b Biochemistry Professor Xuedong Liu's startup, OnKure Therapeutics, raises $51M in series B funding in 2021 Anonymous (not verified) Thu, 03/03/2022 - 13:09 Faculty Highlights Industry Connections Xuedong Liu window.location.href = `/venturepartners/about-us/2021-venture-partners-annual-report`;

Off

Traditional 0 On White ]]> Thu, 03 Mar 2022 20:09:47 +0000 Anonymous 1307 at /biochemistry Lab Venture Challenge /biochemistry/2019/11/19/lab-venture-challenge Lab Venture Challenge Anonymous (not verified) Tue, 11/19/2019 - 00:00 Faculty Highlights Awards Roy Parker Xuedong Liu Published: Nov. 19 ,  2019 • By Mallory Richardson

Lab Venture Challenge awards $900,000 to promising bioscience, physical science and engineering ventures

window.location.href = `/venturepartners/2019/11/19/lab-venture-challenge-awards-900000-promising-bioscience-physical-science-and-engineering`;

Off

Traditional 0 On White ]]> Tue, 19 Nov 2019 07:00:00 +0000 Anonymous 1145 at /biochemistry ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ spinout OnKure Therapeutics enrolls first cancer patient in clinical trial /biochemistry/2019/06/19/cu-boulder-spinout-onkure-therapeutics-enrolls-first-cancer-patient-clinical-trial ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ spinout OnKure Therapeutics enrolls first cancer patient in clinical trial Anonymous (not verified) Wed, 06/19/2019 - 12:28 Faculty Highlights Industry Connections Xuedong Liu By Mallory Richardson • Published: June 21 ,  2019

A new drug therapy for cancer treatment, spun out of research performed in a , may provide better results for patients with solid cancers and hematologic cancers, such as leukemia and lymphoma.

window.location.href = `/venturepartners/2019/06/21/cu-boulder-spinout-onkure-therapeutics-enrolls-first-cancer-patient-clinical-trial`;

Off

Traditional 0 On White ]]> Wed, 19 Jun 2019 18:28:37 +0000 Anonymous 1119 at /biochemistry